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ABSTRACT 
Selective expression of cytokines on the surface of tumors is likely to stimulate 
tumor-infiltrating lymphocytes that are primed and already recognize tumor antigens. 
This may result in enhanced tumor recognition and killing. This gene therapy approach 
may avoid toxicity associated with systemic therapy with high doses of the cytokines 
needed to achieve the same effects. In order to test this concept, we have evaluated an 
IL-2 gene construct that is designed to induce tumor cells to express a membrane bound 
form of IL-2 (IL-2tm). A mammalian plasmid expression vector was designed to express 
a fusion gene consisting of human interleukin 2 with a FCE-Y transmembrane anchor 
derived from a subunit of the FC epsilon receptor. We demonstrated that mRNA and 
protein for the IL-2tm fusion protein was expressed in transfected RD995 tumor cells. 
Expression of the IL-2tm protein on the tumor cell surface membrane was confirmed by 
laser confocal microscopy. In order to assess biological function, RD995 transfected 
with IL-2tm or pCMV2b (empty expression vector) were implanted subcutaneously into 
C3H1HEN mice. Nontransfected RD995 was also implanted subcutaneously for tumor 
growth comparison (control group). RD995 tumor cells (106 or 105 /mouse) transfected 
with IL-2tm grew more slowly than RD995 transfected with pCMV2b or non-transfected 
control RD995 implanted tumors after implantation into syngenic animals. Further 
preclinical evaluation of the IL-2tm gene therapy as a possible cancer treatment is 
underway. 
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INTRODUCTION 
Interleukin 2 is a cytokine produced primarily by T cell lymphocytes that has 
been shown to have anti-tumor effects. I Human IL-2 is a 15-kD glycoprotein composed 
of 133 amino acids.2-3 Produced primarily by CD4+ helper T cells, the cytokine consists 
of four antiparallel alpha helices that are connected by three loops. IL-2 was first 
described as a T cell growth factor for antigen-activated T cells.2 IL-2 is necessary for 
induction and clonal expansion of antigen-specific cytotoxic T cells. In addition, this 
cytokine is a differentiation-maturation factor for B cells and T cells. I8 At high 
concentrations (>600 IU/ml), IL-2 is also the principle cytokine responsible for inducing 
NK cell derived lymphokine-activated killer (LAK) cells. Cytotoxic T and NK 
lymphocytes are believed to be critical for recognition of aberrant or malignant cells and 
eradication of tumors. I, 3-4,12,16 
These antitumor properties provide the basis for IL-2 therapy of cancer. 14 
Intravenous administration of recombinant human IL-2 is FDA approved for treatment of 
advanced melanoma and renal cell carcinoma.17 IL-2 immunotherapy produces responses 
in about 15% of melanoma patients and 20% in renal cell carcinoma patients. 5 
Interestingly, 5-10% of patients that respond to IL-2 innnunotherapy experience a durable 
complete response with up to 15 years follow-up.6 However, IL-2 therapy produces 
severe dose-dependent toxicity that often prevents the patient from completing the IL-2 
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treatment regimen.7 Side effects include weight gain, ascites, dyspnea, pulmonary edema 
and severe hypotension. 
Efforts to circumvent these side effects have led to IL-2 based gene therapy 
protocols. 14 Tumor cells have been engineered to secrete IL-2 into the microenvironment 
surrounding the tumor. Most tumors contain infiltrating CD8+ lymphocytes.23-24 When 
these cells are initially isolated from tumors, they can be activated and clonally expanded 
in the presence of IL-2 to generate tumor specific cytotoxic lymphocytes. Thus, a goal of 
gene therapy is to cause intratumoral secretion of activating cytokines resulting in 
enhanced activation of cytotoxic tumor-infiltrating lymphocytes (TIL) within tumors. 8 
Examples of successful IL-2 based gene therapy have been published. 19 Horton et al. 
evaluated IL-2 gene therapy of murine ovarian cancer.9 Murine ovarian tumors (MOT) 
were treated with an IL-2 plasmid DNA complexed with the cationic lipid, N-(2-
hydroxyethyl)-N ,N-dimethyl-2-3-bis( tetradecyloxy )-l-propanaminium 
bromide/dioleoylphosphatidylethanolamine (DMRIEIDOPE). MOT tumor-bearing mice 
injected i.p. with IL-2 plasmid:DMRIEIDOPE on days 5, 8, and 11 after tumor cell 
implantation demonstrated a significant inhibition of tumor ascites as well as a significant 
increase in survival. By day 26 after tumor cell injection, 10% of the mice treated with 
the control pDNA were still alive compared with 70% of the mice treated with IL-2 
pDNA:DMRIEIDOPE. Furthermore, the peritoneal fluid of mice treated with IL-2 
pDNA: DMRIEIDOPE had an IL-2 specific increase in the levels of interferon gamma 
(lFN-y) and granulocyte stimulating factor (GM-CSF). This study also investigated the 
nature of the inlIDune response to the MOT cells, using nude mice (immunodeficient 
mice without a thymus and without T cells). Only a modest inhibition of tumor growth 
occurred in nude mice, showing that T cells are required for IL-2 gene mediated anti-
tumor effects.9 
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We and others have pioneered a new approach to gene therapy by creating a 
fusion gene encoding a cytokine plus a transmembrane domain. Cell membrane-
expressed cytokines may be able to activate immune cells in close proximity to tumor 
antigens that act to create a specific immune recognition. An added advantage is that low 
level of cytokine expression remains localized to the tumor and is not associated with the 
toxicity of high systemic doses of the cytokine. IO-11 There are two published studies of 
membrane bound cytokines (not IL-2). In the first paper, murine tumor necrosis factor 
alpha (TNFu) was expressed in a membrane bound (nonsecreted) form by Marr using an 
adenoviral vector in a murine transgenic breast cancer model. They were able to reduce 
systemic toxicity with little or no reduction of antitumor activity. 10 
In a second paper, membrane-bound forms ofGM-CSF and IFN-y were created. 11 
Cloned GM-CSF and IFN-y were both bound to a transmembrane domain (gamma single 
chain of the Fc€Rl). EI-Shami showed that surface co-expression ofGM-CSF and IFN-y 
induced a cytotoxic T lymphocyte (CTL) response that protected syngenic mice against 
D122 (clone of Lewis lung carcinoma). Surface co-expression ofGM-CSFIIFN-y also 
protected mice from subsequent rechallenge ofnontransfected D122 tumor cells. The 
researchers also reported that toxic side effects were not detected in the mice. 11 
The purpose of this thesis is to engineer and evaluate a plasmid containing a 
transgene encoding membrane bound IL-2 (IL-2tm). By inducing expression ofIL-2 on 
the surface of tumor cells, we hypothesize that IL-2 will activate tumor infiltrating 
lymphocytes in proximity to tumor antigens. This would increase activation of antigen-
specific T cells and result in destruction of tumor cells expressing tumor-associated 
antigens. The IL-2tm construct was created by joining the gene for human IL-2 with the 
transmembrane domain Fcs-y as previously described by EI-Shami. 11 
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The three objectives of this thesis project were: 1) construction of a plasmid to 
express membrane bound IL-2 protein on the surface of mammalian tumor cells, 2) 
evaluation of the capacity of tumor cells transfected with IL-2tm containing plasmid to 
induce mRNA and protein expression and 3) assessment of biological anti-tumor activity 
ofRD995 tumor cells transfected with the hIL-2+ Fcs-y gene construct. 
MATERIALS AND METHODS 
Insertion of human interleukin 2 into cloning vector 
pBluescript KS and sequence verification 
Plasmid VRII 03 containing the human Interleukin 2 (hIL-2) gene was a gift from 
Vical, Inc. Restriction enzymes Pst! and Bamill (Life Technologies, Gaithersburg, MD) 
were used to excise the hIL-2 gene from the plasmid. The cut VRII03 plasmid was run 
on a low melting point 1% agarose gel (Sigma Chemical Company, St. Louis, MO) and 
the band containing the 1L-2 gene was identified and isolated from the gel using 
GeneCAPSULE TM (Geno Technology, Inc., St. Louis, MO). The expected DNA size 
was 616 base pairs. The identity of the gene was confrrmed by direct DNA sequencing 
(Huntsman Cancer Institute Core Facility, University of Utah, Salt Lake City, UT). 
Cloning vector pBluescript II KS (+/-) (Stratagene, La Joll~ CA) was cut with 
Pst! and Bamill (Life Technologies, Gaithersburg, MD) and run on a low melting point 
1 % agarose gel (Sigma Chemical Company, St. Louis, MO). pBluescript KS was 
isolated from the gel to remove the segment of DNA between PstI and BamHI (the 
stuffer portion). hIL-2 was then ligated into pBluescript KS, by combining 0.5 units of 
T4 DNA Ligase (Boehringer Mannheim, GmbH, Germany), 5 III hIL-2 gene (23 ng/IlI) 
insert with 2 III of cut pBluescript KS (150 ng/ Ill). DH5a ™ Competent Cells (Life 
Technologies, Gaithersburg, MD) were transformed with the ligated cloning vector 
following the protocol in the package insert. Transformed DH5a TM E. coli was plated on 
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ampicillin agar plates (100 flglml) for isolation. Selection of bacterial colonies 
expressing bIL-2 was performed using lacZ color selection of recombinant plasmids. 
Sterile toothpicks were used to select individual white colonies. The colonies were then 
grown in LB media with ampicillin (100 flglml) for 16 h. A Qiagen ™ Plasmid Midi kit 
(Valencia, CA) was used to isolate bIL-2/pBluescript KS. The insertion of intact hIL-2 
gene was verified by DNA based PCR, using the primers (5' TGC TGO ATT TAC AGA 
TGA TIT 3') and (5' CAC TIC CTC CAG AGO TIT G 3'). PCR was run for 32 cycles 
at 55° C annealing for 15 sec, 72° C extension for 30 sec resulting in a 155 base pair 
product, which was verified by direct sequencing. 
Removal of stop codon using PCR directed mutagenesis 
The stop codon in the IL-2 gene was identified. Primers were designed to remove 
this stop codon and add restriction sites BamHI (5' GOA TCC 3') on the sense strand and 
EcoRI (5' GAA TIC 3') on the antisense strand in order to facilitate insertion into a 
mammalian expression vector. The following primers were used (sense 5' AGA ACT 
AGT GOA TCC GCA CCT ACT TCA AGT TCT 3') and (antisense 5' GTC AGG GAA 
TIC AGT CAG TGT TGA GAT GCT TIG 3'). PCR ofhIL-2/pBluescript KS was 
performed using the following parameters: 30 cycles at 60° C annealing for 30 sec, 72° C 
extension for 120 sec, using Herculase™ Enhanced DNA Polymerase (Stratagene, La 
Jolla, CA). The resulting 423 bp PCR product was isolated from a 1% agarose gel as 
described above. Restriction enzymes BamHI and EcoRI were then used to digest the 
isolated bIL-2 gene. The digested hIL-2 PCR product was separated on a 1 % agarose gel 
and isolated as previously described. 
Construction of a hIL-2 fusion gene containing 
a transmembrane domain from FCE-I 
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FCE-Y was chosen to donate a transmembrane domain based on a previously 
published study by EI-Shami. 11 HTAAA91 plasmid encoding FCE- Y was purchased from 
ATCC (Manassas, VA). The Fcs-y gene was excised from the plasmid using restriction 
enzymes BamHI and EcoRI. Ligation of FCE-Y and modified hIL-2 was performed under 
the following conditions: 0.5 units ofT4 DNA Ligase (Boehringer Mannheim, GmbH, 
Germany), 5 ~ll of gel extracted FCE-y, 2 J!l ofhIL-2 gene and 8 J!l of DE PC treated 
water. DH5a ™ Competent Cells were transformed with the ligation product and grown 
on ampicillin agar selection plates. The colonies were screened by PCR using primers 
spanning the fusion product of the IL-2 gene and the transmembrane region of FCE-y (5' 
TGC TGG ATTTAC AGA TGA ITT 3') and (5' CAC ITC CTC CAG AGGTTT G 
3 '). PCR conditions were 32 cycles at 55° C annealing for 15 sec, 72° C extension for 30 
sec. The PCR products were run on a 1% agarose gel and colonies containing hIL-2/ 
FCE- Y (IL-2tm) fusion product were chosen for expansion and grown overnight in LB 
ampicillin broth and isolated with the Qiagen ™ Plasmid Midi kit (Valencia, CA). The 
plasmids were sequenced using PCR based sequencing to verify proper insertion of hIL-
2and to ensure removal of the stop codon. 
Ligation ofhIL-2IFcE- Y fusion gene into the mammalian 
expression vector pCMV2b 
The pCMV2b (Stratagene, La Jolla, CA) expression vector was selected to 
maintain in frame transcription of the hIL-2IFCE- y gene. This vector contains a 
cytomegalovirus promoter along with neomycin and kanamycin resistance selection 
markers. pCMV2b is an N-terminal FLAG® tagging vector. The FLAG® protein was 
included to facilitate tracking of the fusion protein, using a FLAG specific antibody. 
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pCMV2b vector and bIL-21Fc£- 'Y were cut with ApaI and BamHI (Life 
Technologies, Gaithersburg, MD) and gel isolated as previously described. Ligation of 
the vector and gene was performed under the following conditions: 1 unit ofT4 DNA 
Ligase (Boehringer Mannheim, GmbH, Germany), 2 JlI of ligation buffer (provided in 
kit), 14 JlI of ApaI and BamHI cut pCMV2b, 2 JlI of ApaI and BamHI cut hIL-2/ Fc£- 'Y 
and 3 ~tl of DE PC treated water. DH5a ™ Competent Cells (Life Technologies, 
Gaithersburg, MD) were transformed with the resulting plasmid and grown on agar plates 
containing 50 Jlglml kanamycin. The colonies were screened using the same screening 
procedure described previously. Lane 2 was isolated from the gel and sequenced using 
T3 and T7 based primers to verify proper insertion ofhIL-2IFc£- 'Y into the expression 
vector pCMV2b. pCMV2b + bIL-2IFc£- 'Y is designated the IL-2tm vector. 
Transfection ofIL-2tm and pCMV2b into murine 
tumor cells RD995 
RD995 cells were cultured in six-well plates at a concentration of 105 cells per 
well and allowed to adhere overnight. In order to determine the optimum Lipofectin and 
DNA concentrations, Lipofectin (l mglml) (Life Technologies, Gaithersburg, MD) was 
used to transfect RD995 at the following volumes: 2 JlI, 10 JlI, and 20 JlI along with either 
1.0 Jlg or 2.0 Jlg ofIL-2tm using the procedure described in the Lipofectin package 
insert. Cells transfected with pCMV2b empty vector served as a control. Optimum 
LipofectinIDNA concentration was determined based on the number ofRD995 surviving 
selection with 800 Jlglml G418 (Sigma Chemical Company, ST. Louis, MO). 
Screening for IL2tm and pCMV2b mRNA expression 
Using predetennined optimal conditions, RD995 cells were transfected with IL-
2tm (2 ~g) or pCMV2b empty vector (Lipofectin 1 0 ~l) and allowed to grow for 1 week. 
They were then transferred to 200 rrd culture flasks (Coming Costar Corporation, 
Cambridge, MA) containing 30 ml ofRPMI-1640 (BioWhittaker, Walkersville, MD) 
culture media supplemented with 5% fetal calf serum. 
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After expanding RD995 cultures for 1 week, 800 ~glml G418 (Sigma Chemical 
Company, ST. Louis, MO) was added to cultures to select for tumor cells expressing the 
IL-2tm plasmid or the pCMV2b plasmid. Untransfected control cells were universally 
killed by this concentration of G418. Transfected cells were allowed to grow for an 
additional 2 to 3 weeks. Total RNA was subsequently isolated from 1 06 cultured cells 
using TRI reagent (Molecular Research Center, INC., Cincinnati, OH). In order to 
remove residual plasmid DNA, the isolated RNA was treated with 0.6 ~l of DNase (Life 
Technologies, Gaithersburg, MD) followed by phenOl/chloroform extraction. Reverse 
transcription of mRNA was performed under the following conditions: 200 ng total RNA, 
1.0 ~l M-ML V -reverse transcriptase (200 units/~l), 1 hr incubation at 37 0 C. PCR was 
performed on the IL-2tm and pCMV2b cDNA using primers spanning the IL-2 gene and 
the transmembrane fusion domain as previously described. 
Western blot analysis ofIL-2tm protein expression 
in RD995 tumor cells 
One million RD995 cells transfected with IL-2tm using (2.0 ~g ofIL-2tm and 
lOll1 of Lipofectin) were grown in a six well plate containing 5 ml ofRPMI-1640 culture 
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media without G418. Tumor cells were harvested at days 1-5. One million harvested 
cells were washed twice in PBS and lysed in RIP A buffer containing protease inhibitors 
(phenylmethyl sulfonyl fluoride, 200 mM; aprotinin, 1 mg/ml; trypsin/chymotrypsin 
inhibitor, 1 mg/ml; leupeptin, 1 mg/ml; pepstatin A, 1 mg/ml) (Sigma Chemical 
Company, St. Louis, MO). The lysate was sonicated for 10 sec (on ice) and stored at 
minus 20° C until Western blot analysis was performed. Prior to blotting, samples were 
thawed and 50 III of lysate was added to 50 III of 2% SDS and boiled for 5 min. Twenty 
microliters of each sample were then applied to a 12.5% PAGE electrophoresis gel (run 
for 35 min at 200V) and transferred to Immobilon™-P membrane (Millipore, Bedford, 
MA). The membrane was blocked with 5% nonfat dry milk for 2 hr. Subsequently, the 
membrane was washed with Tris-buffered saline-tween (TTBS) and incubated overnight 
with 1 Ilg/ml rabbit anti-IL-2 anti-serum (Santa Cruz Biotechnology, Santa Cruz, 
California) at 4 0 C. The membrane was again washed with TTBS and incubated with 
0.16 Ilg/ml peroxidase-conjugated anti-rabbit IgG antibody (Santa Cruz Biotechnology, 
Santa Cruz, California). Excess peroxidase was removed by washing the membrane with 
TTBS and with one final wash with tris-buffered saline (TBS). Finally, the membrane 
was soaked in Luminol Reagent (Santa Cruz Biotechnology, Santa Cruz, California) for 1 
min and exposed to X-ray film. 
In1ffiunofluorescent antibody staining for nlembrane associated IL-2 
One million RD995 cells transfected with IL-2tm were washed twice in PBS and 
incubated one ice for 30 min with rabbit anti-IL-2 antiserum (10 Jlg/ml) (Santa Cruz 
Biotechnology, Santa Cruz, California) or with monoclonal mouse anti-flag antibody (10 
Jlg/ml) (Stratagene, La Jolla, CA). Cells were then washed with cold PBS+ 1 % sodium 
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azide and incubated for 30 min with anti-rabbit Alexa 568 (10 f.1g/ml) (Molecular Probes, 
Eugene, OR) or with anti-mouse Alexa 488 (10 f.1g/ml), respectively. Parental RD995 
cells and RD995 transfected with empty vector were similarly stained as negative 
controls. The cells were permeablized with 0.1% Triton X-100 (Bio-Rad, Richmond, 
CA) and 0.1 % sodium citrate buffer incubated on ice for 2 minutes. After permeablizing 
the cell membrane, TO-PRO3™ (1 f.1M) (Molecular Probes, Eugene, OR) was added to 
stain the nucleus. Cells were then fixed in 1 % paraformaldehyde for 30 min at room 
temperature. An Olympus Fluoview 200 laser scanning confocal microscope was used to 
visualize the subcellular localization ofIL-2 in cells. 
Evaluation of growth of RD995 cells transfected 
with IL-2tm in C3WHEN mice 
RD995 is a murine spindle cell skin cancer derived from an uv-irradiated 
C3WHEN mouse. Groups of 10 C3HIHEN mice (Charles River Laboratories, 
Wilmington, MA) were implanted subcutaneously with 106,5 x 105 or 105 IL-2tm 
transfected RD995. Equivalent numbers of pCMV2b transfected tumor cells or parental 
tumor cells were implanted to serve as controls. The maximum cross sectional dimension 
of each tumor were measured every other day with calipers and the area of the tumor was 
calculated. 
PCR analysis ofIL-2tm gene expression in excised RD995 tumors 
On day 40 of tumor growth, mice were sacrificed and tumors excised to evaluate 
IL-2tm gene expression. Total RNA was extracted using TRI reagent and RT-PCR was 
perfonned using IL-2tm primers that spanning the fusion gene product as previously 
described. 
Tritiated thymidine ([3HJ-Tdr) uptake by transfected 
RD995 tumors in vitro 
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In order to measure whether IL-2tm transfection altered tumor proliferation, 105 
RD995 tumor cells (transfected either with IL-2tm, pCMV2b or 105 nontransfected 
RD995) were placed into each well of a 96-well tissue culture plate (24 replicates). Cells 
were incubated with 10 fll of [3H]-Tdr (50 JlCi/ml) per well (NENTM Life Science 
Products, Boston, MA) at 37° C for 48 hr. A PHDTM Cell harvester (Cambridge 
Technology Inc., Cambridge, MA) was used to harvest cellular DNA onto glass fiber 
filters (Gelman Sciences Inc., Ann Arbor, MI) and to wash away unincorporated [3H]-
Tdr. The filter paper was allowed to air dry at room temperature for 4 hr, placed in 2 ml 
of scintillation fluid (Perkin Elmer Life Sciences, Boston, MA) and counted for one 
minute/sample on a 2500 TRI-CARB liquid scintillation analyzer (Perkin Elmer Life 
Sciences, Boston, MA). 
Evaluation of biologic activity ofIL-2tm using 
the IL-2 dependent cell line CTLL-20 
In order to test whether the tumor cell expressed IL-2tm protein was biologically 
active, IL-2tm transfected tumor cells were lysed and added to the IL-2 dependent T cell 
line CTLL-20. Lysis of 5 X 106 RD995 cells transfected with IL-2tm or pCMV2b was 
accomplished by snap freezing in liquid nitrogen. The membrane portion of the lysate 
was separated from the cytosol by centrifugation for 15 min at 12,000xg. The cytosol 
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portion was placed into another tube and the membrane portion was reconstituted in an 
equivalent volume (0.5 ml) of RPMI media. One hundred microliters of membrane 
lysate or, cytosol lysate (serial two-fold dilutions) were placed into a 96 well plate (in 
triplicate). One hundred thousand CTLL-20 cells were added to each well. CTLL-20 is 
an IL-2 dependent cell line derived from a C57BL/6 mouse (gift from D. Keith Bishop, 
University of Michigan Medical School). Prior to starting this experiment, IL-2tm 
expression in transfected RD995 cells was verified using RT-PCR and primers that span 
the IL-2 gene and transmembrane domain as previously described. A positive control 
consisted of serial dilutions of 200 IU recombinant hIL-2 (Chiron, Emeryville, CA). The 
plates were allowed to incubate at 37° C for 48 hr, and then each well was pulsed with 10 
JlI of [3H]-Tdr (50 JlCi/ml) for 24 hr. After harvesting, samples were evaluated by 
scintillation counting. 
RESULTS 
Construction of IL-2tm 
To test the hypothesis that membrane expression ofIL-2 would lead to activation 
of T -cells infiltrating into cancers, it was necessary to create a fusion gene containing IL-
2 and a transmembrane domain. The gene for hIL-2 (plasmid VR1103) was acquired as a 
gift from Vical Inc. hIL-2 was removed from pVR1103 because the flanking sequences 
of the hIL-2 gene in the VR1103 vector were unknown. Restriction enzymes PstI and 
BamHI were used to cut the hIL-2 gene from the plasmid. The gene was isolated on a 
1 % agarose gel (Figure 1). The expected hIL-2 size is 339 bp plus 217 extra base pairs 
from pVR1103 (total of616 bp). 
Figure 1. Plasmid VRII03 was cut with restriction enzymes PstI and BamHI. Lane 
2 (see arrow) shows the faint hIL-2 band of 616 base pairs. hIL-2 DNA was then 
isolated from the 1 % agarose gel using the GeneCAPSULETM method. 
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In order to identify the stop codon in hIL-2, hIL-2 was ligated into cloning vector 
pBluescript KS to facilitate sequencing. pBluescript KS was cut with restriction enzymes 
Pstl and BamHI. The gel isolated hIL-2 band (from Figure 1) and the gel isolated cut 
pBluescript KS were ligated together. DNA based primers for hIL-2 were used to 
perform peR on the ligated pBluescript KS+hIL-2. Figure 2 illustrates successful 
ligation ofhIL-2 gene into pBluescript. 
pBluescript KS was sequenced (Figure 3) to identify the stop codon. The stop 
codon was removed by peR directed mutagenesis. DNA based primers were designed to 
amplify the hIL-2 gene without the stop codon. Restriction sites were also incorporated 
onto the ends of the primers to maintain proper orientation and reading frame of the hIL-
2 gene during ligation. Following DNA based peR, the modified IL-2 gene was isolated 
from a 1 % agarose gel (Figure 4). 
Figure 2. hIL-2 was ligated into cloning vector pBluescript KS. DH5«TMCompetent 
cells were transformed with hIL-2/pBluescript KS and screened for recombinant 
plasmids by lacZ color selection. hIL-2 DNA insertion was then verified by DNA 
based peR using primers directed toward hIL-2. PCR was run for 32 cycles 
reSUlting in a 155 base pair product. Plasmid VRII03 was used as a positive control 












Figure 3. T3 promoter based primers were used to sequence hIL-2. Bold 
underlined text indicates beginning and end of the hIL-2 gene. The T AA TT AA stop 
codon was later removed by PCR directed mutagenesis. 
Figure 4. Primers were designed to incorporate restriction sites BamHI (5' GGA 
TCC 3') on the sense strand and EcoRI (5' GAA TTC 3') on the antisense strand in 
order to facilitate insertion of hIL-2 into plasmid HT AAA91 that contains the 
transmembrane domain FCE-Y. Herculase™ Enhanced DNA Polymerase was used 
to amplify hIL-2 for 30 cycles. The 423 base pair band was isolated from the gel. 
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The hIL-2 gene and Fce-r transmembrane domain were each cut with BamHI and 
EcoRI. The hIL-2 (minus the stop codon) construct was ligated upstream and in frame 
with the transmembrane domain Fce-r derived from the plasmid HTAAA91. Fce-r is an 
accessory signaling protein of the Fce receptor that has a minimal extracellular domain. 
DNA sequencing verified that hIL-2 (minus the stop codon) was upstream and in frame 
with Fce-r (Figure 5). 
Lastly, in order to express hIL-2 on the surface of tumors, a mammalian 
expression vector was selected to deliver the hIL-2 +Fce-r fusion gene. pCMV2b 
contains a cytomegalovirus promoter along with neomycin and kanamycin resistance 
selection markers. Additionally, pCMV2b also encodes an N-terminal FLAG® tagging 
protein. We included the FLAG protein for use in identifying hIL-2 expression on the 












Figure 5. T3 promoter based primers were used to sequence hIL-2 + Fc£-y. Bold 
underlined text shows the beginning of hIL-2 and the beginning of the 
transmembrane domain Fc£-y. Sequencing verifies that the stop codon from hIL-2 
has been removed and that hIL-2 was upstream and in frame with the 
transmembrane domain. 
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Restriction enzymes ApaI and BamHI were used to cut HT AAA91 and 
pCMV2b. The IL-2tm (hIL-2+ Fc£-y) construct was then ligated into pCMV2b as 
previously described. IL-2tm was sequenced to verify proper insertion into the 
expression vector. DNA sequencing (Figure 6) demonstrated that IL-2tm was ligated in 
the proper reading frame. 
Screening for IL-2tm and pCMV2b mRNA and protein 
expression in RD995 tumor cells 
Optimal conditions for transfection of RD995 tumor cells with IL-2tnl contained 
within pCMV2b were established experimentally. We subsequently evaluated the ability 
ofpCMV2b vector containing IL-2tm to induce mRNA and protein expression. Total 
RNA was extracted from transfected RD995 tumor cells (2 Jlg IL-2tm and 10 JlI 
lipofectin). The RNA was treated with DNase to remove any residual plasmid derived 
DNA. After reverse transcription, DNA based primers, spanning the hIL-2+ Fc£-y fusion 
gene were used to amplify the IL-2tm fusion gene by DNA based PCR. Figure 7 
demonstrates that IL-2tm mRNA was easily detected in transfected RD995 cells. Control 
cells transfected with pCMV2b did not express this message. 
Expression of IL-2tm protein in transfected RD995 cells was evaluated by 
Western blot analysis. Celllysates were harvested on days 1-5 after transfection and 
analyzed for hIL-2 protein. Figure 8 shows that hIL-2 (18kD) and hIL-2 + 
transmembrane domain (27kD) are both present. Recombinant hIL-2 from Chiron was 
used as a positive control. The native IL-2 produces a band of 15 kD, but multimeric 




















AGC TCCC CGCGGTGGCGGCC GCCCCATGGATTACAAGGATGAC GACGA 
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Figure 6. Sequence analysis demonstrates that IL-2tm has been inserted in the 
correct reading frame into expression vector pCMV2b. The upper bold underlined 
text indicates the initiation start site and the second bold underlined sequence 
identifies the beginning of the transmembrane domain. 
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Figure 7. IL-2tm mRNA expression in RD995 cells transfected with IL-2tm or 
pCMV2b alone. Total RNA was extracted using TRI-REAGENT and treated with 
DNase to remove any residual plasmid DNA prior to reverse transcription. Primers 
were designed to span the hIL-2 gene and the transmembrane domain with an 
expected 500 base pair PCR product. This gel demonstrates that mRNA expression 
is present in cells transfected with IL-2tm, but not empty vector (pCMV2b). 




Figure 8. Western Blot analysis of IL-2tm expression. 106 RD995 cells were 
transfected with IL2-tm. 106 cells were harvested days 1-5 after transfection and 
washed in PBS and lysed in RIP A buffer. The Iysates were applied to a 12.5% 
PAGE electrophoresis gel. Mter electrophoretic transfer to a membrane, and 
blocking steps, membranes were stained with 1 .... g/ml polyclonal rabbit anti-IL-2 
antibody_ Bands were visualized using Luminol on x-ray film. Recombinant hIL-2 
from Chiron was used as a positive control. The positive control shows three 
expected bands of IL-2 (45 kD, 30 kD and 15 kD) on the right side of blot. Non-
transfected RD995 cells were used as a negative control. IL-2tm appears to generate 
both hIL-2 bound to transmembrane (27kD) and free hIL-2 (18kD) on left side of 
blot. 
Immunofluorescent antibody staining for surface bound 
hIL-2 in RD995 tumor cells 
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Laser confocal microscopy was utilized to demonstrate that IL-2 was being 
expressed on the surface oftransfected RD995 cells. RD995 cells transfected with IL-
2tm or pCMV2b (106 cells) were stained with anti-hIL-2 or anti-FLAG (Figures 9 and 
10). TO-PRO3™ nuclear stain was applied to the cells after they were stained with anti-
hIL-2 or anti-FLAG. Untransfected RD995 or RD995 stained with secondary antibody 
alone were used as negative controls and also showed no staining (data not shown). 
Evaluation of growth of RD995 cells transfected 
with IL-2tm in C3H1HEN mice 
We hypothesized that expression ofIL-2tm protein on tumor cell surface 
membranes would alter immunologic recognition in mice. We therefore evaluated the 
growth ofIL-2tm transfected RD995 tumor cells in syngenic mice~ RD995 cells 
transfected with IL-2tm were implanted subcutaneously into groups of 10 C3H1HEN 
mice (106, 5 x 105 or 105 tumor cells per mouse). Mice implanted with equivalent 
numbers of nontransfected RD995 cells or empty vector (PCMV2b) transfected RD995 
cells were used as controls. Prior to implantation of tumors, IL-2tm InRNA expression in 
transfected RD995 cells was verified using RT-PCR and primers that span the IL-2 gene 
and the transmembrane domain (Figure 11). 
The maximum cross sectional area of each tumor was measured with calipers 
every other day. The results are shown in Figure 12. Growth ofIL-2tm transfected 
tumors was markedly reduced compared to parental or empty vector transfected RD995. 
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Figure 9. Laser confocal microscopy of IL-2tm and pCMV2b transfected RD995. 
Cells were stained with anti-hIL-2 antiserum and TO-PRO3™ (l,..,Mlml) in order to 
visualize the nucleus. (A) Red staining of cells transfected with IL-2tm 
demonstrated surface membrane expression of IL-2. (B) RD995 transfected with 
empty pCMV2b vector indicates no hIL-2 expression. 
A B 
Figure 10. Laser confocal microscopy of FLAG-stained RD995 transfected with IL-
2tm or pCMV2b. (A) Green staining demonstrates FLAG antigen expression in 
RD995 transfected with IL-2tm. (B) RD995 transfected with pCMV2b 
demonstrated no staining. 
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Figure 11. Prior to subcutaneous implantation of RD995 transfected with IL-2tm or 
pCMV2b, tumor cells were assayed for mRNA expression of IL-2tm. Primers 
designed to span the hIL-2 gene and the transmembrane domain generated the 
expected 500 base pair product. This gel demonstrates that mRNA expression is 
present, which was absent from parental tumor (neg) and empty vector transfected 
RD995 (PCMV2b). 
The experiment was terminated on day 40 due to excessive size of tumors in control 
mice. On day 40, tumors in mice implanted with 106 IL-2tm RD995 cells showed 
reduced growth (52% smaller than in mice bearing pCMV2b RD995 and 59% smaller 
than parental RD995 tumor cells) (Figure 12). The group implanted with 5 x 105 IL-2tm 
RD995 tumor cells also showed reduced tumor growth (31 % smaller tumors than the 
pCMV2b RD995 group and 30% smaller tumors than the parental RD995 group). No 
tumors grew in any groups of mice implanted with only 105 cells (data not shown). On 
day 40, mice from each group were sacrificed, the tumors excised and assayed for 
persistence ofIL-2tm transgene expression. No residual IL-2tm mRNA could be 
detected in any tumors harvested on day 40, suggesting IL-2tm was lost prior to this time 
(data not shown). 
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Figure 12. Growth of subcutaneous tumors in C3H1HEN mice injected with 106 
RD995 transfected with IL-2tm, RD995 transfected with pCMV2b (empty vector) or 
RD995. The difference in growth rates between IL-2tm and the control groups was 
significant (p=O.OII) by ANOV A. 
Evaluation of the effect ofIL-2tm and 
pCMV2b or RD995 proliferation 
The previous experiment demonstrated that RD995 cells transfected with IL-2tm 
grow at a slower rate than RD995 transfected with pCMV2b or parental RD995. A trivial 
explanation for this could be that tumor cells transfected with IL-2tnl might have 
decreased proliferative potential due to some nonspecific cellular effect of the transgene. 
An in vitro thymidine incorporation assay was used to evaluate this possibility. This 
experiment showed that RD995 transfected with IL-2tm or pCMV2b had similar 
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thymidine incorporation as nontransfected RD995 (mean plus or minus SD of24 wells) 
(Figure 13). 
Evaluation of biological activity of IL-2tm 
expressed in transfected RD995 
The biological activity of IL-2tm was analyzed utilizing a murine cytotoxic T cell 
line that is dependent on IL-2 for growth. Recombinant human IL-2 is known to result in 
increased proliferation of CTLL-20 (measured by incorporated [3H]-TdR).2o-21 
A standard curve was generated using human recombinant hIL-2. It was found 
that 17 IV of lL-2 stimulated a measurable proliferation of CTLL-20. The relationship 
between thymidine incorporation and h1L-2 concentration was almost linear between 17 
and 200 IV. This assay showed that RD995 cells transfected with IL-2tm or pCMV2b 
failed to induce detectable proliferation of CTLL-20. This implies less than 17 IV of 
biologically active IL-2 was expressed per 105 tumor cells. 
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Figure 13. Analysis of thymidine incorporation in 105 RD995, RD995 transfected 
with pCMV2b or IL-2tm after 48hr in culture. 
DISCUSSION 
Using molecular genetic approaches, a fusion gene containing human interleukin 
2 (hlL-2) and a transmembrane domain (IL-2tm) derived from FCB-Y was created. The 
purpose of this construct was to provide a transmembrane anchor allowing hIL-2 to be 
expressed at the cell membrane of transfected cells, in close proximity to tumor 
infiltrating lymphocytes (TIL cells) and tumor specific antigens. II The trans gene was 
subsequently cloned into a mammalian expression vector (PCMV2b). The correct 
orientation of the trans gene was verified by DNA sequencing. 
IL-2tm was transfected into murine RD995 tumor cells. Cells were evaluated for 
IL-2tm mRNA and protein expression. RT-PCR was performed with DNA based 
primers that span the IL-2 gene and the FCB-Y gene and were used to distinguish the 
transgene from any native IL-2 mRNA (ifpresent). This sequence has no known 
mammalian homologues. DNase treatment was used to exclude carry over of the IL-2tm 
containing pCMV2b plasmid. Using this RT-PCR assay, we found that IL-2tm mRNA 
was expressed in transfected RD995 tumor cells but not in pCMV2b transfected or 
parental RD995 cells. Western blot analysis was performed to detect IL-2tm protein in 
transfected RD995 cells. IL-2tm was detectable in RD995 transfected with IL-2tm (a 
27kD protein). Protein expression persisted for at least 5 days following transfection. 
Interestingly, two bands ofIL-2 were seen on the Western blot. One band correlated with 
the expected 27 kD IL-2tm protein. The other band correlated with IL-2 (18kD), which 
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suggests cleavage of the IL-2tm from the transmembrane anchor. The parental RD995 
tumor was shown not to produce any IL-2 protein. Further investigation will be 
necessary to determine the exact site of cleavage and the enzyme responsible. IL-2tm 
protein expression on the surface of cells was confirmed by immunofluorescent staining 
ofIL-2tm transfected RD995 cells. Anti-hIL-2 antiserum staining ofRD995 cells 
transfected with IL-2tm showed that hIL-2 was expressed on the surface membrane by 
laser confocal microscopy. Anti-FLAG antibody was used to visualize the FLAG 
neoprotein that had been added to the N-terminus ofIL-2tm. Immunofluorescent staining 
for FLAG also confirmed expression at the surface ofIL-2tm transfected RD995. 
Parental RD995 or RD995 transfected with pCMV2b (empty expression vector) did not 
exhibit surface expression of FLAG or IL-2 protein. 
To test the biologic activity of the transgene, groups of 10 syngenic (C3H1HEN) 
mice were injected with 105,5 x 105 or 106 tumor cells subcutaneously. Mice implanted 
with equivalent numbers of pCMV2b or parental tumors served as controls. Expression 
of the transgene in IL-2tm transfected RD995 cells was verified at the start of the 
experiment. RD995 tumor cells (106 or 105 Imouse) transfected with IL-2tm grew more 
slowly than RD995 transfected with pCMV2b or nontransfected control RD995 
implanted tumors after implantation into syngenic animals. The experiment was 
terminated on day 40 due to the large size of tumors in control mice. To assess whether 
the trans gene was still expressed, mice were sacrificed and excised tumors were assayed 
for mRNA expression ofIL-2tm or pCMV2b. It was found that mRNA expression had 
been lost. A trivial explanation for the decreased proliferation rate of RD995 cells 
transfected with IL-2tm (in C3H1HEN mice) might be due to nonspecific effects of the 
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transgene. Tritiated thymidine incorporation into transfected and nontransfected tumor 
cells established that these cells proliferate at essentially at the same rate, thus excluding 
this possibility. 
Biological activity ofIL-2tm was analyzed by utilizing an IL-2 dependent cell 
line?0-21 This assay (with a sensitivity of 17 U IL-2/well) was unable to detect bioactive 
IL-2 in 105 tumor cells. This finding most likely may indicate very low levels ofIL-2tm 
expression. Alternately we have considered the possibility of expression of inactive IL-
2tm protein. If further experiments determine that IL-2tm is indeed inactive, we would 
propose that conformational issues might playa role. Hydrophobicity plots (data not 
shown) suggest that the residual intracellular domain of Fct-y may be folded and 
externally expressed on the cell surface along with the IL-2 protein. This could sterically 
hinder IL-2 from interacting with the IL-2 receptor. Alternately, the cell lysis procedure 
may inactivate IL-2. These possibilities are currently being tested. 
We have therefore commenced additional modifications of the IL-2 vector to 
optimize biologic function. First, IL-2tm was designed to include the FLAG tagging 
protein to facilitate identification and tracking of the IL-2tm protein. The FLAG 
sequence may alter the tertiary protein structure ofIL-2tm. It is strongly inlmunogenic 
and could initiate immunological recognition of the IL-2tm protein in future multi-
injection experiments. The FLAG sequence has therefore been removed. Second, IL-2tm 
contained extraneous amino acids that were part of the multiple cloning site in the 
expression vector, which have also been deleted. Third, the mammalian expression 
vector, pCMV2b, does not contain an enhancer. IS, 22 mRNA expression levels may be 
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greatly increased by using an expression vector that includes an enhancer in addition to a 
promoter. The effects of these design changes are currently being tested. 
The mechanism that resulted in decreased growth of RD995 cells transfected with 
IL-2tm in C3H1HEN mice is also being further investigated. Additional tumor cell lines 
will be transfected with modified IL-2tm plasmid (modifications described in the 
previous paragraph) to evaluate growth potential in vivo. Histological studies of tumor 
infiltrating lymphocytes and studies of tumor-specific T cell activation are planned to 
help evaluate the mechanism of the antitumor effect. 
The eventual goal of this project is to produce a gene construct that can be used in 
gene therapy of cancer in humans. Activated TIL cells may be able to destroy tumors by 
recognizing tumor-associated antigens. Furthermore, activated TIL cells may have the 
ability to migrate throughout a patient" s body and destroy tumor metastases. By further 
developing the IL-2tm vector, we may be a step closer to testing a practical gene therapy 
reagent for use against human cancer. 
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